Roche 89bio deal involves a $2.4 billion acquisition, targeting MASH with a late-stage drug that could impact the market significantly.
Author: PharmaSignal News Desk
A snapshot of August 2025’s top pharma and biopharma developments — highlighting $185.28B in deal value, four FDA approvals, and EMA’s regulatory focus on AI
Precigen FDA approval for Papzimeos granted without confirmatory trial, benefiting adult patients with recurrent respiratory papillomatosis.
AbbVie acquires bretisilocin for up to $1.2 billion, marking a significant move in psychedelic treatments.
LB Pharmaceuticals IPO raises $285M, marking the first major biotech IPO since February, focusing on schizophrenia treatment.
Novartis Monte Rosa partnership focuses on immunology, potentially worth $5.7 billion.
FDA guidance non-opioid pain medicines includes speedy approval pathways to address the opioid crisis with new drug options.
Sun Pharma Halol Plant faces an FDA export ban due to ongoing safety violations, affecting drug exports to the US.
Takeda appoints Rhonda Pacheco to lead its U.S. business, leveraging her experience with Zepbound’s launch.
Novo Nordisk layoffs affect 9,000 employees globally as part of restructuring to address obesity drug competition.